Orexin-A Half-Life

What Is Orexin-A Half-Life?

Half-life is the time for serum concentration to decrease to 50%. Orexin-A half-life is approximately 1-2 hours in blood—quite short. However, this doesn't mean effects last only 2 hours. Orexin-A crosses the blood-brain barrier and accumulates in orexin-sensitive brain regions, producing functional effects lasting 8-12+ hours despite short serum half-life.

Serum Half-Life vs. Functional Half-Life

Serum half-life (1-2 hours) describes how quickly the peptide disappears from blood. Functional half-life (8-12+ hours) describes how long biological effects persist. Orexin-A produces sustained neuroadaptation: receptor upregulation, intracellular signaling cascades, and circuit-level changes that persist long after serum concentrations normalize. This is why single morning injections produce all-day wakefulness effects.

Time to Peak Plasma Concentration

Following subcutaneous or intramuscular injection, peak serum orexin-A concentration occurs 30-90 minutes post-injection (varies by injection depth, local blood flow, and individual metabolism). Noticeable wakefulness effects typically begin 30-60 minutes post-injection. Maximum subjective alertness plateaus 2-4 hours post-injection as brain concentrations reach saturation.

Duration of Wakefulness Effects

Single morning injection (1-3 mg) produces 8-16 hours of enhanced wakefulness and alertness. Effects are strongest 2-6 hours post-injection; secondary sustained plateau extends to 12-16 hours. By 16-20 hours post-injection, wakefulness effects largely normalize to baseline, allowing natural sleep drive to resume. This timeline is why injection timing relative to sleep is critical.

Individual Variation in Orexin-A Pharmacokinetics

Factors affecting half-life and duration: body weight (heavier individuals may have slightly shorter functional duration due to distribution volume), liver/kidney function (rare impact due to short serum half-life, but chronic dysfunction may alter metabolism), injection site (IM injections peak slightly faster than SubQ), and individual receptor sensitivity (genetically influenced).

Factors Extending Orexin-A Duration

Adequate nutrition (fed state extends duration slightly), hydration, sleep quality night before injection, and aerobic fitness all support sustained orexin-A effects. Sleep deprivation paradoxically shortens perceived duration (users report wakefulness effects ending earlier if fatigued). Cardiovascular fitness improves circulation and distribution, supporting longer functional duration.

Factors Shortening Orexin-A Duration

Heavy exercise 1-2 hours post-injection may accelerate clearance slightly. Fever or acute illness can alter pharmacokinetics. Medications affecting liver metabolism (CYP3A4 inducers) could theoretically shorten duration, though clinical evidence is limited. Poor nutrition or significant fatigue reduces perceived duration.

Dosing Implications of Pharmacokinetics

Short serum half-life but long functional duration means: single morning injection is sufficient for all-day effects, twice-daily dosing is rarely necessary, and evening redosing should be avoided (effects persist into sleep). For sleep timing: inject morning to early afternoon; effects normalize 12-16 hours later, allowing natural sleep at 10 PM when morning injection occurred.

Building Tolerance and Pharmacokinetic Changes

With daily use over weeks to months, users may develop tolerance: wakefulness effects persist the same duration but feel subjectively weaker. This likely reflects receptor desensitization or increased enzymatic inactivation rather than altered serum half-life. Cycling (4-6 weeks on, 1 week off) or periodic dose increases restore sensitivity.

Saturation and Dose-Response Relationship

Orexin-A follows dose-dependent kinetics: 1 mg produces noticeable effects; 2-3 mg produces maximal practical effects; 5+ mg provides no additional benefit and increases side effects (diminishing returns). Brain receptor saturation likely occurs at 2-3 mg doses. Increasing dose doesn't meaningfully extend duration; it increases intensity and risk of overstimulation.

Timing Relative to Key Activities

For morning alertness: inject 6-9 AM; peak effects arrive by midday. For training (afternoon): inject 1-2 hours pre-training; peak capacity occurs during training. For cognitive work: inject morning; sustained plateau extends through afternoon. For sleep optimization: inject morning; effects normalize by evening (10-12 hours later), allowing sleep without suppression.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).